A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

NCT01192191 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg
DRUG: Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

Sponsor

GlaxoSmithKline